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AbsTrACT
Introduction Variants in the GBA1 gene have been 
identified as a common risk factor for Parkinson’s 
disease (PD). in addition to pathogenic mutations (those 
associated with gaucher disease), a number of ’non- 
pathogenic’ variants also occur at increased frequency 
in PD. Previous studies have reported that pathogenic 
variants adversely affect the clinical course of PD. The 
role of ’non- pathogenic’ GBA1 variants on PD course 
is less clear. in this study, we report the effect of GBA1 
variants in incident PD patients with long- term follow- up.
Methods The study population consisted of patients 
in the cambridgeshire incidence of Parkinson’s disease 
from general Practice to neurologist and Parkinsonism: 
incidence, cognition and non- motor heterogeneity in 
cambridgeshire cohorts. Patients were grouped into 
non- carriers, carriers of ’non- pathogenic’ GBA1 variants 
and carriers of pathogenic GBA1 mutations. survival 
analyses for time to development of dementia, postural 
instability and death were carried out. cox regression 
analysis controlling for potential confounders were used 
to determine the impact of GBA1 variants on these 
outcome measures.
results GBA1 variants were identified in 14.4% of 
patients. Pathogenic and ’non- pathogenic’ GBA1 variants 
were associated with the accelerated development 
of dementia and a more aggressive motor course. 
Pathogenic GBA1 variants were associated with earlier 
mortality in comparison with non- carriers, independent 
of the development of dementia.
Discussion GBA1 variants, including those not 
associated with gaucher disease, are common in PD and 
result in a more aggressive disease course.
InTroDuCTIon
Heterozygous mutations in the GBA1 gene have 
been identified as a common risk factor for Parkin-
son’s disease (PD), being found in approximately 
5% of patients.1–4 Biallelic pathogenic mutations 
result in the lysosomal storage disorder, Gaucher 
disease (GD).5 In addition to the known pathogenic 
mutations associated with GD, there are a number 
of ‘non- pathogenic’ GBA1 variants that are not 
associated with GD but that are found at increased 
frequency in patients with PD, including the 
common E326K and T369M variants.6–9 Carrying 
a pathogenic GBA1 mutation conveys an earlier age 
of onset10 11 and adversely affects the clinical course 
of PD, manifested by an increased risk of cognitive 
decline and dementia1 10 12–18 and increased rate 
of motor progression.1 10 12 19 20 However, some 
studies have found no effect on motor progression 
in GBA1 mutation- associated PD.14 15 17 Few studies 
have commented on the effect of GBA1 mutations 
on mortality in PD, though some have suggested 
that survival time is reduced in GBA1 mutation 
carriers.10 16 The clinical significance of carrying 
a ‘non- pathogenic’ GBA1 variant is disputed14 21 
though the E326K variant in particular has been 
associated with an adverse clinical course in PD in 
some studies.20 22
We previously reported on the epidemiology 
of GBA1 mutations in incident PD.1 Here we 
present long- term follow- up data of incident PD 
cases carrying pathogenic and ‘non- pathogenic’ 
variants in the GBA1 gene from two community- 
based cohorts: the ‘Cambridgeshire Incidence 
of Parkinson’s disease from General Practice to 
Neurologist’ (CamPaIGN) and ‘Parkinsonism: Inci-
dence, Cognition and Non- motor heterogeneity in 
Cambridgeshire’ (PICNICS) cohorts. Advantages of 
this study over some previously published studies 
include the long duration of follow- up, along with 
the fact that both cohorts consisted of community- 
based patients with newly diagnosed PD.
MeThoDs
Patients
The study population consisted of patients in 
the CamPaIGN and PICNICS cohorts—both 
community- based incident PD cohorts table 1 and 
online supplementary table 3).23 PD diagnosis was 
determined by the UK Parkinson’s Disease Society 
Brain Bank Criteria. The CamPaIGN cohort was 
recruited between 2000 and 2002, and subjects 
were followed up at 2 yearly intervals for up to 18 
years. The PICNICS cohort was recruited between 
2006 and 2013, and subjects have been followed up 
at 18 monthly intervals, so far for up to 11.4 years. 
Inclusion and exclusion criteria for these cohorts 
are summarised in online supplementary table 1.
Written informed consent was obtained from all 
subjects.
Motor, cognitive and neuropsychiatric assess-
ments were completed at each time point including 
the Unified Parkinson’s Disease Rating Scale 
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Table 1 Patient demographics
non- carriers All GBA1 variants P value
GBA1 non- pathogenic 
variant carriers
Pathogenic GBA1 
mutation carriers P value
Number 214 48 – 31 17 –
Sex M:F 127:87 32:16 0.348 22:9 10:7 0.459
Age at diagnosis 69.2 (9.8) 68.3 (8.9) 0.569 68.7 (10.1) 67.5 (6.3) 0.785
Years of follow- up 6.9 (4.2) 6.1 (3.4) 0.255 6.8 (3.6) 6.2 (2.8) 0.791
Years in education 11.9 (3.1) 11.3 (2.5) 0.253 11.3 (2.5) 11.5 (2.7) 0.510
Total UPDRS at baseline 51.8 (19.6) 54.2 (16.8) 0.431 56.2 (18.3) 50.0 (15.2) 0.452
Motor UPDRS at baseline 31.6 (12.5) 35.1 (12.0) 0.072 35.7 (12.1) 35.1 (13.2) 0.168
Hoehn and Yahr at baseline 1.7 (0.7) 2.0 (0.8) 0.02 2.0 (0.74) 2.0 (0.8) 0.067
PIGD score at baseline 0.75 (0.55) 0.85 (0.47) 0.225 0.86 (0.52) 0.79 (0.34) 0.563
Tremor score at baseline 0.59 0.41) 0.61 (0.41) 0.744 0.75 (0.42) 0.51 (0.35) 0.119
Baseline levodopa equivalent dose 185.9 mg (238.7) 204.4 mg (241.1) 0.594 166.1 mg (214.1) 274.1 mg (277.0) 0.290
MMSE at baseline 28.5 (1.4) 28.2 (1.9) 0.274 27.9 (2.1) 28.6 (1.4) 0.150
BDI at baseline 7.3 (5.3) 6.8 (5.0) 0.629 7.8 (5.6) 4.9 (2.9) 0.180
NART at baseline 116.1 (61.9) 111.3 (11.3) 0.609 109.7 (10.7) 113.2 (12.0) 0.873
PDQ-39 at baseline 24.7 (19.8) 26.4 (19.8) 0.602 32.5 (22.3) 17.5 (9.2) 0.057
SDs shown in brackets.
P values are shown for comparison between non- carriers and all variant carriers as determined by independent samples t- tests and χ2 tests, and for comparison between non- 
carriers, ‘non- pathogenic’ variant carriers and pathogenic variant carriers, as determined by one- way analysis of variance and χ2 tests. Statistically significant results highlighted 
in bold.
BDI, Beck Depression Inventory; F, female; M, male; MMSE, Mini- Mental State Examination; NART, National Adult Reading Test; PDQ-39, Parkinson’s Disease Questionnaire 39; 
PIGD, postural instability and gait disability; UPDRS, Unified Parkinson’s Disease Rating Scale.
(UPDRS) in the CamPaIGN cohort, Movement Disorders 
Society UPDRS (MDS- UPDRS) in the PICNICS cohort, Mini- 
Mental State Examination (MMSE), Hoehn and Yahr (HY) stage, 
levodopa equivalent dose, Beck Depression Inventory, National 
Adult Reading Test and Parkinson’s Disease Questionnaire-39. 
For the CamPaIGN cohort, estimated MDS- UPDRS scores were 
calculated as described previously.24 Postural instability and gait 
disability (PIGD) and tremor scores were calculated for the 
CamPaIGN cohort as described here.25 We adapted this method 
to allow calculation of similar motor phenotypes in the PICNICS 
cohort, using the mean value of the UPDRS- MDS scores for 
questions 2.10 (tremor history), 3.15 (postural tremor), 3.16 
(kinetic tremor) and 3.17 (rest tremor) for tremor score, and 
questions 2.12 (walking and balance history), 2.13 (freezing 
history), 3.10 (gait examination) and 3.13 (posture examina-
tion) for PIGD score. GBA1 variants were identified through 
sequencing of the GBA1 gene targeted at exons 1 to 11 in 250 
patients, as described previously.1 A further 127 patients under-
went targeted screening using an Illumina Multi- Ethnic Geno-
typing Array (MEGA) ChIP for specific GBA1 variants (online 
supplementary figure 1).26
survival and regression analyses
Subjects were grouped into non- carriers and carriers of any 
GBA1 variant (GBA1- PD). The GBA1- PD group was further 
stratified into carriers of pathogenic mutations and carriers of 
‘non- pathogenic’ variants, as indicated below. Hereafter, vari-
ants referred to as ‘pathogenic’ are those associated with the 
development of GD in the homozygous or compound heterozy-
gous state, and variants referred to as ‘non- pathogenic’ are those 
that are not associated with the development of GD. All patients 
in whom sequencing had been undertaken were included in 
survival analyses, as well as additional patients in whom any 
GBA1 variant was detected on the MEGA ChIP array. Patients in 
which only MEGA ChIP screening was performed that were not 
found to carry a GBA1 variant were excluded, given the possi-
bility that they carried an undetected GBA1 variant that had not 
been screened for. For subgroup analysis, subjects that only had 
genotyping with the Mega ChIP array in which no GBA1 variant 
was identified, or in which a ‘non- pathogenic’ variant was iden-
tified (n=6), were excluded to ensure that there no patients with 
missed pathogenic mutations were included in the non- carrier or 
‘non- pathogenic’ variant carrier groups.
Time to mortality, postural instability and dementia were 
selected as outcome measures, as these represent important clin-
ical milestones in the progression of PD. Kaplan- Meier curves and 
Cox Regression analyses controlling for potential confounders 
as detailed below were used for comparison between the groups. 
Development of postural instability was defined as time to reach 
HY stage three (HY3) or PIGD score of 2 or more, and dementia 
was defined as a MMSE score of 24 or less, with fulfilment of 
Diagnostic and Statistical Manual of Mental Disorders IV criteria 
(functional impairment (as defined by Schwab and England score 
of 70% or less) with cognitive deficits in at least two domains 
and exclusion of other causes of cognitive dysfunction). The 
CamPaIGN and PICNICS cohort studies predated establish-
ment of the Movement Disorder Society PD dementia criteria. 
Patients were only considered to have reached these outcomes if 
these criteria were fulfilled at all subsequent visits.
statistical analysis
All statistical tests were performed on SPSS V.25 software. Inde-
pendent samples t- tests were used to compare between non- 
carriers and carriers of all GBA1 variants. Levene’s test was first 
performed to ensure that equality of variance could be assumed. 
One- way analysis of variance tests were used for comparison 
between non- carriers and carriers of ‘non- pathogenic’ or patho-
genic GBA1 variants. χ2 tests were used to compare sex distri-
bution. For survival analysis, log- rank values are reported, with 
comparison with the non- carrier group.
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Table 2 Time to dementia
non- carriers All GBA1 variants non- pathogenic variants Pathogenic mutations
Number 214 48 25 17
Estimated mean time to dementia (years) 13.7 (12.6 to 14.7) 8.6 (7.2 to 10.0) 8.3 (6.4 to 10.2) 8.3 (6.2 to 10.3)
Estimated median time to dementia (years) * 8.5 (6.9 to 10.1) 8.3 (5.4 to 11.3) 8.5 (4.1 to 12.9)
5- year survival without dementia (%) 85.3 (SE 2.7) 80.2 (SE 6.3) 82.3 (SE 8.0) 74.0 (SE 11.2)
10- year survival without dementia (%) 68.4 (SE 4.3) 45.7 (SE 9.8) 43.2 (SE 12.5) 43.2 (SE 16.0)
15- year survival without dementia (%) 64.2 (SE 5.8) 0 0 0
Log- rank p value – 0.013 0.014 0.109
HR – 2.1 (1.2 to 3.9; p=0.013) 1.8 (0.9 to 3.8; p=0.110) 3.6 (1.6 to 8.3; p=0.003)
Long- term follow- up data for progression to dementia in PD patients without GBA1 variants compared with those carrying any GBA1 variant, a pathogenic GBA1 mutation or a 
GBA1 ‘non- pathogenic’ variant.
HR determined by Cox regression analysis controlling for age at diagnosis, sex and baseline MMSE score. Ninety- five per cent CI for HR and estimated mean and median shown 
in brackets. Log- rank p values shown for comparison between the GBA1 groups and the non- carrier group. Statistically significant results highlighted in bold.
*Fewer than half reached outcome
MMSE, Mini- Mental State Examination.
Figure 1 effect of GBA1 variants on development of dementia in PD. (a) survival analysis for time to dementia in carriers of any GBA1 variant compared 
with non- carriers. (B) subgroup survival analysis for time to dementia in carriers of pathogenic GBA1 mutations, ‘non- pathogenic’ variants and non- carriers. 
statistical significance as determined by log- rank tests indicated by asterisk. PD, Parkinson’s disease.
resulTs
Incidence and spectrum of GbA1 abnormalities
GBA1 variants were present in 36 out of the 250 patients in 
which sequencing was performed (14.4%). Pathogenic muta-
tions were present in 11 of these patients (4.4 %), which 
included N370S (n=3), L444P (n=3), R463C (n=1), G10S 
(n=1), N426K (n=1), R48W (n=1) and R257Q (n=1). Isolated 
‘non- pathogenic’ variants were present in 25 of these patients 
(10.0 %). These included c.762 18T>A (n=8), E326K (n=7), 
T369M (n=7), E388K (n=1), L119L (n=1) and c.589 86A>G) 
(n=1). The carrier of the pathogenic R48W variant carried a 
concomitant E326K variant, and the carrier of the pathogenic 
N426K variant carried a concomitant c.762 18T>A variant. 
These were both included in the pathogenic variant group for 
subgroup analyses. Variants were identified in 12 of the 127 
patients (9.4%) in which MEGA ChIP analysis was performed. 
These included the pathogenic N370S (n=4), R463C (n=1) and 
G10S (n=1) variants and the ‘non- pathogenic’ T369M (n=3), 
E326K (n=2) and E388K (n=1) variants.
After excluding those patients in which only MEGA ChIP 
genotyping was performed that were not identified to carry a 
GBA1 variant, these combined cohorts contained 214 non- 
carriers and 48 carriers of GBA1 variants. Mean follow- up times 
were 8.0 years (maximum 18.0 years) for the CamPaIGN cohort 
(n=115) and 5.8 years (maximum 11.4 years) for the PICNICS 
cohort (n=147).
Cognitive decline and risk of dementia
Baseline cognitive function did not differ between variant carriers 
and non- carriers, with no significant differences in MMSE scores 
at initial assessment (table 1). Carriers of any GBA1 variant had 
an increased risk of progression to dementia compared with non- 
carriers (table 2 and figure 1). Cox regression analysis controlling 
for age at diagnosis, sex and baseline MMSE score revealed that 
development of dementia was significantly more likely in carriers 
of any GBA1 variant, compared with non- carriers, with an HR 
of 2.1 (95% CI 1.2 to 3.9, p=0.013). At the 10- year time point, 
fewer than half of the variant carriers remained dementia free, 
in comparison with 68.4% of non- carriers. At 15 years, 64.2% 
of surviving non- carriers remained dementia- free. All patients in 
the GBA1 carrier group had developed dementia or died prior 
to the 15- year time point. The estimated mean time to dementia 
was approximately 5 years earlier in variant carriers, compared 
with non- carriers (table 2).
Subclassification of the variant carrier group into those with 
pathogenic mutations and those with ‘non- pathogenic’ variants 
revealed a significantly increased risk of progression to dementia 
in carriers of pathogenic variants, with an HR of 3.6 (95% CI 1.5 
to 8.3, p=0.003). In carriers of ‘non- pathogenic’ variants, there 
was a non- significant trend towards increased risk of dementia 
(HR 1.8 (95% CI 0.9 to 3.8, p=0.11).
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Table 3 Time to HY3
non- carriers All GBA1 variants non- pathogenic variants Pathogenic mutations
Number 213 48 25 17
Estimated mean time to HY3 (years) 6.8 (5.9 to 7.6) 4.7 (3.4 to 5.9) 4.6 (3.0 to 6.3) 4.4 (3.0 to 5.9)
Estimated median time to HY3 (years) 6.0 (4.6 to 7.4) 3.0 (2.5 to 3.5) 2.8 (2.5 to 3.1) 4.4 (2.6 to 6.2)
5- year survival without postural instability (%) 57.0 (SE 3.6) 32.5 (SE 7.3) 32.0 (SE 10.0) 32.4(SE 11.8)
10- year survival without postural instability (%) 28.7 (SE 4.1) 9.6 (SE 5.9) 10.7 (SE 7.0) 0
15- year survival without postural instability (%) 7.7 (SE 3.9) 9.6 (SE 5.9) 10.7 (SE 7.0) 0
Log- rank p value – 0.013 0.074 0.095
HR – 1.7 (1.2 to 2.6; p=0.006) 1.7 (1.0 to 2.9; p=0.035) 1.9 (1.0 to 3.4; p=0.036)
Long- term follow- up data for progression to postural instability in PD patients without GBA1 variants compared with those carrying any GBA1 variant, a pathogenic GBA1 
mutation or a GBA1 ‘non- pathogenic’ variant.
HR determined by Cox regression analysis controlling for age at diagnosis, sex, baseline HY score, baseline UPDRS motor score and baseline PIGD score. Ninety- five per cent CI 
for HR and estimated mean and median shown in brackets. Log- rank p values shown for comparison between the GBA1 groups and the non- carrier group. Statistically significant 
results highlighted in bold.
HY3, Hoehn and Yahr stage three; PIGD, postural instability and gait disability; UPDRS, Unified Parkinson’s Disease Rating Scale.
Figure 2 effect of GBA1 variants on development of postural instability in PD. (a and c) survival analysis for time to hY3 and PigD score of 2 or more, 
respectively, in carriers of any GBA1 variant compared with non- carriers. (B and D) subgroup survival analysis for time to hY3 and PigD score of 2 or more, 
respectively, in carriers of pathogenic GBA1 mutations, ‘non- pathogenic’ variants and non- carriers. statistical significance as determined by log- rank tests 
indicated by asterisk. hY3, hoehn and Yahr stage three; PigD, postural instability and gait disability.
Motor progression
The baseline HY stage was lower in non- carriers compared with 
carriers (table 1), though there were no significant differences 
between the subgroups. There were no differences in baseline 
UPDRS motor score, PIGD score or levodopa equivalent dose 
between any of the groups. The risk of progression to postural 
instability was increased in the GBA1- PD group in comparison 
with the non- carrier group (table 3 and figure 2). At 5 years 
from diagnosis, 67.5% of the GBA1- PD group had reached 
HY3, compared with 43% of non- carriers. After controlling for 
potential confounders (age at diagnosis, sex, baseline HY score, 
baseline UPDRS motor score and baseline PIGD score), the risk 
of progression to HY3 was significantly greater in both carriers 
of ‘non- pathogenic’ variants and pathogenic mutations, with an 
HR of 1.7 (95% CI 1.0 to 2.9, p=0.035) and 1.9 (95% CI 1.0 to 
3.4, p=0.036), respectively (figure 2 and table 3).
Time to PIGD score of 2 or more was also determined as a 
measure of motor progression. Pathogenic variants were associ-
ated with an increased risk of progression to PIGD score of 2 or 
more, with a HR of 2.8 (95% CI 1.4 to 5.7, p=0.005). There 
was no significant increased risk of progression to PIGD score 
of two or more in carriers of ‘non- pathogenic’ variants (table 4).
Mortality
Mean time to mortality was approximately 1 year earlier in 
carriers of any GBA1 variant compared with non- carriers 
(table 5 and figure 3). At 15 years from diagnosis, only 5.3% 
of GBA1 variant carriers were surviving, compared with 20.1% 
of non- carriers. When controlling for age and sex, the risk of 
mortality was increased in carriers of pathogenic mutations in 
comparison with non- carriers with an HR of 2.1 (95% CI 1.0 to 
4.1, p=0.043) but not in those carrying ‘non- pathogenic’ vari-
ants (table 5).
To explore whether the increase in mortality associated with 
pathogenic GBA1 variants was attributable to the development 
of dementia, the dementia outcome was added into the Cox 
regression model, along with age and sex. The increased risk of 
mortality associated with carrying any GBA1 variant persisted 
after controlling for dementia status (HR 2.0 (95% CI 1.0 to 4.1, 
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Table 4 Time to PIGD score of 2 or more
non- carriers All GBA1 variants non- pathogenic variants Pathogenic mutations
Number 214 48 25 17
Estimated mean time to PIGD ≥2 (years) 7.7 (7.2 to 8.3) 6.8 (5.6 to 7.9) 6.9 (5.3 to 8.5) 5.7 (4.4 to 7.0)
Estimated median time to PIGD ≥2 (years) 8.6 (7.4 to 9.9) 6.0 (5.1 to 7.0) 6.0 (5.1 to 7.0) 4.9 (3.1 to 6.6)
5- year survival to PIGD ≥2 (%) 76.1 (SE 3.2) 62.6 (SE 8.1) 71.5 (SE 9.9) 48.8 (SE 13.9)
10- year survival to PIGD ≥2 (%) 40.9 (SE 5.6) 37.9 (SE 8.8) 39.0 (SE 12.0) 30.5 (SE 13.5)
Log- rank p value – 0.094 0.335 0.066
HR – 1.9 (1.1 to 3.2; p=0.015) 1.6 (0.8 to 3.1; p=0.178) 2.8 (1.4 to 5.7; p=0.005)
Long- term follow- up data for progression to postural instability in PD patients without GBA1 variants compared with those carrying any GBA1 variant, a pathogenic GBA1 
mutation or a GBA1 ‘non- pathogenic’ variant.
HR determined by Cox regression analysis controlling for age at diagnosis, sex, baseline HY score, baseline UPDRS motor score and baseline PIGD score. Ninety- five per cent CI 
for HR and estimated mean and median shown in brackets. Log- rank p values shown for comparison between the GBA1 groups and the non- carrier group. Statistically significant 
results highlighted in bold.
HY3, Hoehn and Yahr stage three; PIGD, postural instability and gait difficulty score; UPDRS, Unified Parkinson’s Disease Rating Scale.
Table 5 Time to mortality
non- carriers All GBA1 variants non- pathogenic variants Pathogenic mutations
Number 214 48 25 17
Estimated mean time to death (years) 10.6 (10.0 to 11.3) 9.4 (8.4 to 10.5) 10.0 (8.7 to 11.3) 9.5 (7.8 to 11.3)
Estimated median time to death (years) 10.0 (9.3 to 10.7) 9.4 (8.3 to 10.6) 10.0 (8.9 to 11.1) 8.5 (7.7 to 9.3)
5- year survival (%) 89.2 (SE 2.2) 93.4 (SE 3.7) 96.0 (SE 3.9) 100.0
10- year survival (%) 49.6 (SE 3.9) 39.8 (SE 8.8) 49.7 (SE 11.6) 29.8 (SE 14.1)
15- year survival (%) 20.1 (SE 3.9) 5.3 (SE 5.0) 7.8 (SE 7.3) 0
Log- rank p value – 0.169 0.639 0.275
HR – 1.5 (1.0 to 2.3; p=0.061) 1.2 (0.7 to 2.0; p=0.567) 2.1 (1.0 to 4.1; p=0.043)
Long- term follow- up data for progression to time to mortality in PD patients without GBA1 variants compared with those carrying any GBA1 variant, a pathogenic GBA1 
mutation or a GBA1 ‘non- pathogenic’ variant.
HR determined by Cox regression analysis controlling for age at diagnosis and sex. Ninety- five per cent CI for HR and estimated mean and median shown in brackets. Log- rank p 
values shown for comparison between the GBA1 groups and the non- carrier group. Statistically significant results highlighted in bold.
PD, Parkinson’s disease.
p=0.046)), suggesting that the relationship was independent of 
the development of dementia. Causes of death in each group are 
shown in online supplementary table 2.
DIsCussIon
In this study, we have described the clinical course of incident 
GBA1- PD for up to 18 years from the time of diagnosis, which 
is a longer follow- up period than any previous study. We have 
demonstrated that GBA1 variants confer an increased risk of 
dementia, faster motor progression and mortality in PD, in 
keeping with previous reports. Importantly, in addition to 
pathogenic GBA1 mutations, variants generally considered to be 
‘non- pathogenic’ were found to adversely affect disease course 
in GBA1- PD.
By studying patients with incident PD for up to 18 years, this 
study has uniquely described the natural history of GBA1- PD. 
Most prior longitudinal studies of GBA1- PD have employed 
prevalent cohorts in which variation in disease duration may 
confound the results, and many other studies have used clinic- 
based cohorts that may be disproportionately represented 
by atypical or severe cases. The two cohorts analysed in this 
study were community based and thus more representative of 
the general PD population. Another strength of this study was 
the inclusion of patients with GBA1 variants that do not cause 
GD, which occur at increased incidence in PD. These variants 
were termed ‘non- pathogenic’ to differentiate them from vari-
ants that cause GD, though taking into account results from 
this and previous studies, they should not be considered to be 
non- deleterious.
Of the patients that had undergone genetic sequencing, 14% 
carried a GBA1 variant, with 4.4% carrying a pathogenic muta-
tion2–4 27 previously associated with GD. The frequency of patho-
genic mutations was similar to that seen in previous studies. The 
prevalence of any GBA1 variant was higher than that seen in 
other studies, probably due to the fact that we included non- 
coding variants such as c.762 18T>A, which has been reported 
as a potential risk factor for PD, though its importance is not 
clear.28 The most common variants were c.762 18T>A, E326K 
and T369M, which accounted for almost two- thirds of all vari-
ants. Carriers of these variants are a particularly interesting 
group to study, as their clinical significance is much less clear 
than that of so- called ‘pathogenic’ GBA1 mutations.
We found that GBA1 variants were generally associated with a 
more aggressive disease course. Diagnosis of dementia and devel-
opment of postural instability were chosen as outcome measures, 
since these represent important milestones in the clinical 
progression of PD.29 Consistent with previous studies, carriers of 
pathogenic mutations had an increased risk of reaching both of 
these milestones. Carriers of any GBA1 variant had a projected 
mean time to dementia that was approximately 5 years earlier 
than in non- carriers, while the estimated mean time to devel-
opment of postural instability was approximately 2 years earlier 
than that seen in non- carriers. Carriers of pathogenic muta-
tions had a 3.6- fold greater risk of development of dementia 
than in non- carriers and a 1.9- fold greater risk of progression 
to HY3. Importantly, carriers of variants not associated with GD 
conveyed a similar risk of development of postural instability in 
comparison with non- carriers, with a trend towards greater risk 
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Figure 3 effect of GBA1 variants on time to death in PD. (a) survival analysis for time to death in carriers of any GBA1 variant compared with non- 
carriers. (B) subgroup survival analysis for time to death in carriers of pathogenic GBA1 mutations, ‘non- pathogenic’ variants and non- carriers. PD, 
Parkinson’s disease.
of dementia. These variants have previously been reported to 
have little effect on clinical course in PD,14 though it is possible 
that such effects would be missed due to short follow- up times 
and heterogeneous populations. Carriers of the common E326K 
variant have been shown to have an increased risk of dementia 
and motor progression in comparison with non- carriers in one 
US- based study.20 However, in a large meta- analysis of GBA1 
variants in PD, there was no association between development of 
PD and the E326K variant.4 This study population was enriched 
for individuals from Jewish, Portuguese and Asian populations, 
in which the E326K accounts for a lower proportion of GBA1 
variants than in other populations, which may account for the 
lack of association in this analysis.3 30
We also found a significantly increased risk of mortality over 
the study period in carriers of pathogenic GBA1 variants, in 
which the risk of death was approximately twofold greater than 
that in non- carriers, with a mean time to mortality approxi-
mately 1 year earlier. This observation was not attributable to the 
increased incidence of dementia in GBA1 variant carriers, since 
the effect persisted after controlling for dementia status. Other 
factors (such as immobility, adverse drug effects and non- motor 
features) may contribute to the observed increase in mortality 
in GBA1- PD. ‘Non- pathogenic’ variants were not associated 
with an increased risk of mortality, though the time to mortality 
was non- significantly reduced in this group. The impact of 
GBA1 variants on PD progression may lie on a spectrum, with 
pathogenic mutations conveying a greater biological effect than 
‘non- pathogenic’ variants. As such, our study may have been 
underpowered to detect a small reduction in time to mortality 
associated with ‘non- pathogenic’ variants, and it would be inter-
esting to explore this in a larger cohort.
Age of disease onset has previously been reported to be 
reduced in PD associated with GBA1 mutations.10 13 27 31 In this 
study, age of onset did not differ based on GBA1 status. The 
mean age of onset in both carriers of pathogenic mutations and 
carriers of ‘non- pathogenic’ variants in GBA1 was approximately 
2 years earlier than in non- carriers, and it may be that this study 
was underpowered to detect such a difference in age at onset.
The observation that ‘non- pathogenic’ GBA1 variants 
adversely affect the prognosis of PD patients is important. This 
significantly increases the proportion of patients with PD in 
which GBA1 abnormalities play a potentially pathogenic role, in 
comparison with considering GD- causative mutations as the only 
variants that alter PD course. Given that GBA1 mutations are 
associated with the specific pathology of lysosome–autophagy 
system dysfunction,32 it is possible that the optimal treatment 
approach in this group of patients will involve drugs that are able 
to restore activity of this system. As such treatments emerge, it 
may become important to screen patients with PD for variants 
in the GBA1 gene, so that precision medicine can be applied, 
and our data suggest that it will be important to screen for a 
much broader range of variants than those previously identified 
as ‘pathogenic’.
The ‘pathogenic’ mutations associated with GD result in 
significant reduction in glucocerebrosidase enzyme activity, 
which underlies its clinical manifestations.5 33 However, poly-
morphisms such as E326K result in a relatively minimal reduc-
tion in enzyme activity,22 and the fact that these predispose to 
PD without being associated with GD, supports the concept 
that the pathogenic mechanisms of GBA1- PD are distinct from 
those of GD. This means that putative treatments for GBA1- PD 
may need to correct glucocerebrosidase folding and structure, or 
restore activity of dysfunctional pathways (such as the lysosome- 
autophagy system), rather than simply restoring glucocerebrosi-
dase enzyme activity.
We acknowledge that there are a number of limitations with 
our study. While we have controlled for relevant potential 
confounders in our survival analyses, data regarding prodromal 
features of PD that may influence prognosis (eg, rapid eye 
movement sleep- behaviour disorder) were not available. We 
have reported on the time from diagnosis, rather than time 
from symptom onset, to the development of clinical milestones, 
which may not truly reflect disease duration. However, the time 
of symptom onset is difficult to determine accurately, since many 
prodromal features may not be attributed to PD, which would 
potentially introduce bias.
These cohorts predated the development of the MDS criteria 
for PD dementia. Cognitive status was measured in these cohorts 
with MMSE, though other cognitive examinations are now 
favoured. In order to maximise the accuracy of dementia diag-
nosis in these cohorts, we employed strict criteria that reflect the 
MDS criteria for PD dementia, including a requirement for irre-
versible deficits in multiple cognitive domains accompanied by 
functional impairment. Though we included baseline MMSE as a 
covariate in our Cox regression model for time to dementia, it is 
not known how many patients had mild cognitive impairment at 
baseline, which may be expected to influence prognosis. Because 
assessments were performed every 2 years for the CamPaIGN 
cohort and every 18 months for the PICNICS cohort, it was not 
possible to determine the exact time of the onset of dementia 
or progression to HY3 or PIGD score of 2 or more, which was 
determined as the midpoint between the assessment at which 
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the patient had reached the outcome measure and the prior 
assessment.
Another limitation of our study is the relatively limited sample 
size. We have attempted to address this by using two homo-
geneous incident cohorts from the same population base but 
separated in time.23 However, 115 patients were excluded from 
survival analyses as they had only undergone limited genetic 
screening, meaning that it was possible that they harboured 
unidentified, potentially clinically significant GBA1 variants. 
The sequencing of GBA1 conferred major benefits in this study, 
as a more comprehensive method for identifying both pres-
ence of absence of GBA1 variants. While we acknowledge that 
complete sequencing reads could not be achieved in all patients 
(as previously described in Winder- Rhodes et al1 2013), we 
feel that the use of sequencing data allowed us to assign GBA1 
variant carrier status with maximum possible accuracy. Further 
strengths of this study are the long duration of follow- up of up 
to 18 years, and the fact that our cohorts consisted of incident 
PD patients recruited from the community, allowing follow- up 
from diagnosis to the development of key clinical milestones in 
a representative population. As such we have presented the first 
long- term data on the effect of GBA1 variants on mortality in 
an incident PD population and detected significant differences 
in the natural history of PD associated with ‘non- pathogenic’ 
GBA1 variants, which may have been missed in previous studies, 
probably due to their limited follow- up durations.
In conclusion, long- term follow- up of the CamPaIGN and 
PICNICS cohorts confirms that GBA1 mutations adversely 
affect clinical course. Importantly, carriers of GBA1 variants that 
are often considered to be ‘non- pathogenic’ had a significantly 
worse clinical course than non- carriers. GBA1 variants therefore 
contribute to the pathogenesis and clinical features of more than 
10% of patients with PD, making them a particularly important 
genetic subgroup. Since GBA1 abnormalities appear to be asso-
ciated with specific pathogenic mechanisms, it may be that the 
optimal disease- modifying approach differs in this group than in 
the wider PD population, with important implications for future 
clinical trials.
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